- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 9 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 18 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Drug Pipelines
- January 2018
- 17 Pages
Global
From €9513EUR$10,000USD£8,098GBP
- Report
- December 2021
- 120 Pages
Global
From €2378EUR$2,500USD£2,024GBP
- Report
- August 2022
Global
From €752EUR$790USD£640GBP
- Report
- August 2022
United States
From €1846EUR$1,940USD£1,571GBP
- Report
- August 2022
Global
From €1132EUR$1,190USD£964GBP
- Report
- August 2022
United States
From €1846EUR$1,940USD£1,571GBP
- Report
- August 2021
Global
From €3796EUR$3,990USD£3,231GBP
- Report
- August 2021
Europe
From €3254EUR$3,420USD£2,769GBP
- Report
- August 2021
Global
From €3796EUR$3,990USD£3,231GBP
- Report
- August 2021
Europe
From €3254EUR$3,420USD£2,769GBP
- Report
- February 2021
Global
From €2816EUR$2,960USD£2,397GBP
The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more